Company Directory - Research & Development
We are a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. We are taking a multi-program, multi-technology platform approach, assembled through internal development, collaborations, and acquisitions.
Vivoryon Therapeutics has two decades of successful history in bringing pharmaceutical innovation to patients in need. Our programs are based on dedicated research, top-level discovery and determined development.
We are tackling some of the most difficult challenges in genomic research. This demands science at scale; a visionary and creative approach to research that pushes the boundaries of our understanding in ever new and exciting ways.
Wren Therapeutics is a spin-off company from the University of Cambridge (UK) and Lund University (Sweden) focussed on protein misfolding diseases. Wren Therapeutics is advancing an entirely novel approach to address this class of diseases, based on decades of research from its scientific founders focused on the chemical kinetics of the protein misfolding process.
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology.
bioeq GmbH is active in the development of biosimilar drugs for global markets in compliance with the stringent quality standards required for approval and distribution in the EU, US and other highly regulated countries. Therefore quality platforms according to current GCP and GMP standards are established.
c-LEcta is a fully integrated industrial biotechnology company located in Leipzig, Germany. The company currently employs about 100 people and has established itself as leading player in the realization of high-value biotech products for regulated markets, either as in-house developments or in close cooperation with the industry.
o2h discovery is a premier Contract Research Organisation providing integrated chemistry and biology services for collaborative research.
riboxx pharmaceuticals develops and manufactures GMP TLR3 ligands for immunotherapy of cancer or virus diseases. The drugs developed at riboxx belong to the class of Toll-like-Receptor 3 agonists (TLR3) and RIG-I-like-Receptor (RLR) agonists. The drug substance of these drugs is RNA (ribonucleic acid).
We are a cutting-edge Contract Research Organisation (CRO). We provide research, analysis and consultancy to the food, life science and consumer goods sectors, partnering with SEMs and all the top 15 global pharmaceutical and FMCG companies.
